WO2003035619A8 - Inhibiteurs de la tyrosine kinase - Google Patents

Inhibiteurs de la tyrosine kinase

Info

Publication number
WO2003035619A8
WO2003035619A8 PCT/US2002/033962 US0233962W WO03035619A8 WO 2003035619 A8 WO2003035619 A8 WO 2003035619A8 US 0233962 W US0233962 W US 0233962W WO 03035619 A8 WO03035619 A8 WO 03035619A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
tyrosine kinase
kinase inhibitors
present
receptor
Prior art date
Application number
PCT/US2002/033962
Other languages
English (en)
Other versions
WO2003035619A1 (fr
Inventor
B Wesley Trotter
Original Assignee
Merck & Co Inc
B Wesley Trotter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, B Wesley Trotter filed Critical Merck & Co Inc
Publication of WO2003035619A1 publication Critical patent/WO2003035619A1/fr
Publication of WO2003035619A8 publication Critical patent/WO2003035619A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés capables d'inhiber, de moduler et/ou de réguler la transduction de signal de la tyrosine kinase de type récepteur et de type non récepteur. Les composés de la présente invention possèdent une structure de base comprenant un 2-carboxamidopyrrole. La présente invention concerne également des sels de qualité pharmaceutique, des hydrates et des stéréo-isomères de ces composés.
PCT/US2002/033962 2001-10-25 2002-10-21 Inhibiteurs de la tyrosine kinase WO2003035619A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34300001P 2001-10-25 2001-10-25
US60/343,000 2001-10-25

Publications (2)

Publication Number Publication Date
WO2003035619A1 WO2003035619A1 (fr) 2003-05-01
WO2003035619A8 true WO2003035619A8 (fr) 2003-07-03

Family

ID=23344243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033962 WO2003035619A1 (fr) 2001-10-25 2002-10-21 Inhibiteurs de la tyrosine kinase

Country Status (1)

Country Link
WO (1) WO2003035619A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035744A1 (fr) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Marqueurs biologiques predictifs d'une reaction anticancereuse aux inhibiteurs kinase du recepteur du facteur de croissance 1 analogue a l'insuline
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (fr) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
EP2401614A1 (fr) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
WO2011109584A2 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (fr) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Thérapie anticancéreuse combinatoire
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
EP3044593A4 (fr) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Traitement du cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1139754A4 (fr) * 1998-12-31 2002-12-18 Sugen Inc Composes 3-heteroarylidenyl-2-indolinone utilises pour modulation de l'activite de la proteine kinase et dans la chimiotherapie du cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity

Also Published As

Publication number Publication date
WO2003035619A1 (fr) 2003-05-01

Similar Documents

Publication Publication Date Title
WO2004014300A3 (fr) Inhibiteurs de la tyrosine kinase
WO2004014851A3 (fr) Inhibiteurs de tyrosine kinases
WO2003035615A3 (fr) Inhibiteurs de tyrosine kinase
WO2003035616A3 (fr) Inhibiteurs de la tyrosine kinase
WO2003035619A8 (fr) Inhibiteurs de la tyrosine kinase
WO2003035614A3 (fr) Inhibiteurs de la tyrosine kinase
WO2002046183A3 (fr) Composes de pyrroline substitues par l'indazolyle comme inhibiteurs de kinase
WO2001064681A3 (fr) Composes de 3-(pyrolyllactone)-2-indolinone comme inhibiteurs des kinases
WO2006047479A3 (fr) Inhibiteurs de c-fms kinase
WO2006050109A3 (fr) Nouveaux inhibiteurs de kinase
WO2000043373A3 (fr) Inhibiteurs de kinase
MXPA02005844A (es) Inhibidores de cinasas de proteina.
WO2001019828A3 (fr) Inhibiteurs de kinase utilises comme agents therapeutiques
WO2000002576A3 (fr) Egf-genistein utilise pour la prevention de la restenose
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
EP0766676A4 (fr) Composes et procede destines a inhiber la phosphodiesterase iv
WO2004009597A3 (fr) Pyrazolopyrimidines en tant qu'inhibiteurs de kinases
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2002081728A3 (fr) Inhibiteurs quinoline des kinases hyak1 et hyak3
WO2003086315A3 (fr) Inhibiteurs de la tyrosine kinase
WO2005009373A3 (fr) Inhibiteurs de tyrosine kinase
AU2002247063A1 (en) Antisense modulation of casein kinase 2-beta expression
WO2003086314A3 (fr) Inhibiteurs de la tyrosine kinase
AU2003258922A1 (en) PYRAZOLO (4,3c) CINNOLINE COMPOUNDS AS INHIBITORS OF ITK KINASE ACTIVITY
WO2002060868A3 (fr) Inhibiteurs de la prenyl-proteine transferase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 18/2003 UNDER (22) REPLACE "23 OCTOBER 2002 (23.10.2002)" BY "21 OCTOBER 2002 (21.10.2002)"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP